Affordable Access

deepdyve-link
Publisher Website

Remdesivir: Review of pharmacology, pre‐clinical data and emerging clinical experience for COVID‐19

Authors
  • Jorgensen, Sarah CJ1
  • Kebriaei, Razieh2
  • Dresser, Linda D3, 4
  • 1 Sinai Health System, Canada , (Canada)
  • 2 Wayne State University, USA , (United States)
  • 3 University Health Network, Canada , (Canada)
  • 4 University of Toronto, Canada , (Canada)
Type
Published Article
Journal
Pharmacotherapy
Publisher
John Wiley and Sons Inc.
Publication Date
May 23, 2020
Identifiers
DOI: 10.1002/phar.2429
PMID: 32446287
PMCID: PMC7283864
Source
PubMed Central
Keywords
License
Unknown
External links

Abstract

The global pandemic of novel coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has created an urgent need for effective antivirals. Remdesivir (formerly GS‐5734) is a nucleoside analogue pro‐drug currently being evaluated in COVID‐19 clinical trials. Its unique structural features allow high concentrations of the active triphosphate metabolite to be delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis. In pre‐clinical models, remdesivir has demonstrated potent antiviral activity against diverse human and zoonotic β‐coronaviruses, including SARS‐CoV‐2. In this article we critically review available data on remdesivir with an emphasis on biochemistry, pharmacology, pharmacokinetics and in vitro activity against coronaviruses as well as clinical experience and current progress in COVID‐19 clinical trials.

Report this publication

Statistics

Seen <100 times